Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$3.04 USD
+0.27 (9.75%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $3.10 +0.06 (1.97%) 7:12 PM ET
5-Strong Sell of 5 5
F Value F Growth C Momentum F VGM
Brokerage Reports
Aquestive Therapeutics, Inc. [AQST]
Reports for Purchase
Showing records 61 - 80 ( 402 total )
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Management and Board Additions; 2Q22 Financials; Raising PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Wedbush Healthcare Conference - That''s A Wrap; Key Takeaways
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Q2: EPIPHAST II Data in Q3; Delay Continues for Potential Libervant Approval
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Final EPIPHAST Data Provides Positive Surprise; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Results from Final Two Arms of Part 3 of EPIPHAST; EPIPHAST II Study Underway
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Results From Final Two Arms of Part 3 of EPIPHAST; EPIPHAST II Study Underway
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L